Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.77
DSCO's Cash to Debt is ranked higher than
62% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. DSCO: 2.77 )
DSCO' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: 2.77

Equity to Asset 0.50
DSCO's Equity to Asset is ranked higher than
63% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. DSCO: 0.50 )
DSCO' s 10-Year Equity to Asset Range
Min: -20   Max: 0.93
Current: 0.5

-20
0.93
F-Score: 3
Z-Score: -11.60
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2453.48
DSCO's Operating margin (%) is ranked higher than
54% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. DSCO: -2453.48 )
DSCO' s 10-Year Operating margin (%) Range
Min: -619900   Max: -834.65
Current: -2453.48

-619900
-834.65
Net-margin (%) -2619.03
DSCO's Net-margin (%) is ranked higher than
54% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. DSCO: -2619.03 )
DSCO' s 10-Year Net-margin (%) Range
Min: -920000   Max: -850.13
Current: -2619.03

-920000
-850.13
ROE (%) -124.76
DSCO's ROE (%) is ranked higher than
57% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. DSCO: -124.76 )
DSCO' s 10-Year ROE (%) Range
Min: -575.17   Max: -65.45
Current: -124.76

-575.17
-65.45
ROA (%) -70.50
DSCO's ROA (%) is ranked higher than
58% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. DSCO: -70.50 )
DSCO' s 10-Year ROA (%) Range
Min: -186.83   Max: -56.04
Current: -70.5

-186.83
-56.04
ROC (Joel Greenblatt) (%) -2342.08
DSCO's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. DSCO: -2342.08 )
DSCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2623.52   Max: -199.97
Current: -2342.08

-2623.52
-199.97
EBITDA Growth (3Y)(%) -19.40
DSCO's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. DSCO: -19.40 )
DSCO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55   Max: 22.5
Current: -19.4

-55
22.5
EPS Growth (3Y)(%) -20.80
DSCO's EPS Growth (3Y)(%) is ranked higher than
67% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. DSCO: -20.80 )
DSCO' s 10-Year EPS Growth (3Y)(%) Range
Min: -61.7   Max: 25.5
Current: -20.8

-61.7
25.5
» DSCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

DSCO Guru Trades in Q2 2013

Jim Simons 12,392 sh (New)
» More
Q3 2013

DSCO Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q1 2014

DSCO Guru Trades in Q1 2014

George Soros 166,400 sh (New)
» More
Q2 2014

DSCO Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DSCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out $1.53 - $2.32 $ 1.17-36%0
George Soros 2014-03-31 New Buy$2.14 - $2.73 $ 1.17-51%166400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.50
DSCO's P/B is ranked higher than
81% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. DSCO: 3.50 )
DSCO' s 10-Year P/B Range
Min: 1.51   Max: 68
Current: 3.5

1.51
68
P/S 59.50
DSCO's P/S is ranked higher than
70% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. DSCO: 59.50 )
DSCO' s 10-Year P/S Range
Min: 19.17   Max: 5370
Current: 59.5

19.17
5370
EV-to-EBIT -1.57
DSCO's EV-to-EBIT is ranked higher than
51% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DSCO: -1.57 )
DSCO' s 10-Year EV-to-EBIT Range
Min: -18.9   Max: 0.6
Current: -1.57

-18.9
0.6
Current Ratio 5.91
DSCO's Current Ratio is ranked higher than
78% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. DSCO: 5.91 )
DSCO' s 10-Year Current Ratio Range
Min: 0.35   Max: 19
Current: 5.91

0.35
19
Quick Ratio 5.87
DSCO's Quick Ratio is ranked higher than
79% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. DSCO: 5.87 )
DSCO' s 10-Year Quick Ratio Range
Min: 0.35   Max: 19
Current: 5.87

0.35
19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.96
DSCO's Price/Net Cash is ranked higher than
92% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. DSCO: 3.96 )
DSCO' s 10-Year Price/Net Cash Range
Min: 1.2   Max: 177.75
Current: 3.96

1.2
177.75
Price/Net Current Asset Value 3.96
DSCO's Price/Net Current Asset Value is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. DSCO: 3.96 )
DSCO' s 10-Year Price/Net Current Asset Value Range
Min: 1.2   Max: 177.75
Current: 3.96

1.2
177.75
Price/Tangible Book 3.50
DSCO's Price/Tangible Book is ranked higher than
85% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. DSCO: 3.50 )
DSCO' s 10-Year Price/Tangible Book Range
Min: 0.48   Max: 62.85
Current: 3.5

0.48
62.85
Price/Median PS Value 0.22
DSCO's Price/Median PS Value is ranked higher than
98% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. DSCO: 0.22 )
DSCO' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 13.42
Current: 0.22

0.01
13.42
Earnings Yield (Greenblatt) -63.70
DSCO's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. DSCO: -63.70 )
DSCO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 180.7   Max: 1813985.5
Current: -63.7

180.7
1813985.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DYBN.Germany,
Discovery Laboratories Inc was incorporated as a Delaware corporation in 1992. The Company is a specialty biotechnology company engaged in creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine. Its proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. The Company is developing its KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. IT is also developing novel drug delivery technologies potentially to enable efficient delivery of its aerosolized KL4 surfactant. The Company is initially engaged in improving the management of respiratory distress syndrome (RDS) in premature infants. It has developed a disposable aerosol-conducting airway connector for infants that is intended to simplify the delivery of aerosolized medications and other inhaled therapies to critical-care patients requiring ventilatory support. The Company has exclusive rights to its CAG technology for use with pulmonary surfactants for all respiratory diseases and conditions. In addition, it hold in the U.S. exclusive rights to the CAG technology for use with certain non-surfactant drugs to treat various pediatric and adult respiratory indications in hospitals and other health care institutions. It has also developed a novel, disposable aerosol-conducting airway connector that is intended to simplify the delivery of aerosolized medications, including its aerosolized KL4 surfactant, and inhaled therapies to infants requiring ventilatory support in the NICU and PICU. AEROSURF, AFECTAIR, AFECTAIR DUO, DISCOVERYLABS, SURFAXIN, SURFAXIN LS, and WARMING CRADLE are the Company's registered and common law trademarks. The Company's development, manufacture, distribution, marketing and advertising of drug, device, and combination drug-device products are subject to extensive regulation by federal, state and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for DSCO

Headlines

Articles On GuruFocus.com
Discovery Laboratories Inc. Reports Operating Results (10-Q) Nov 15 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q/A) Nov 15 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q) May 10 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q) Nov 09 2009 
Discovery Laboratories Inc. Reports Operating Results (10-Q) Aug 10 2009 
Discovery Laboratories Inc. Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
Discovery Laboratories Sees Mystery In Recent Stock Gyrations Dec 11 2014
Discovery Labs Partners with March of Dimes on 2015 Prematurity Awareness Campaign Nov 19 2014
Discovery Labs Partners with March of Dimes on 2015 Prematurity Awareness Campaign Nov 19 2014
DISCOVERY LABORATORIES INC /DE/ Financials Nov 15 2014
10-Q for Discovery Laboratories, Inc. Nov 09 2014
DISCOVERY LABORATORIES INC /DE/ Files SEC form 10-Q, Quarterly Report Nov 07 2014
Discovery Laboratories posts 3Q loss Nov 06 2014
Discovery Laboratories posts 3Q loss Nov 06 2014
Discovery Labs Reports Third Quarter 2014 Financial Results Nov 06 2014
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 06 2014
Discovery Labs Reports Third Quarter 2014 Financial Results Nov 06 2014
Discovery Labs Announces Organizational Change and Enhanced Expertise in Neonatology Oct 30 2014
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Termination of a Material Definitive Agreement,... Oct 30 2014
Discovery Labs Announces Organizational Change and Enhanced Expertise in Neonatology Oct 30 2014
Discovery Labs to Report 2014 Third Quarter Financial Results and Hold Conference Call on Thursday,... Oct 29 2014
Discovery Labs to Report 2014 Third Quarter Financial Results and Hold Conference Call on Thursday,... Oct 29 2014
Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized... Oct 23 2014
Discovery Labs Announces Strategic Collaboration With Battelle For AEROSURF® Program Oct 23 2014
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 15 2014
Discovery Labs Announces Strategic Collaboration With Battelle For AEROSURF® Program Oct 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK